moatshark My

All holdings

Ptc Therapeutics

PTCT

Source: the SEC Form 13F filings of the managers we follow, latest for Q3 2026. How we use them

Managers holding
1
In their latest 13F (Q3 2026)
See who
Value held
$2.0m
Combined value at quarter end
Last quarter
1 bought
0 sold or trimmed
Price at Q2 ’26 end
$81.57

Prices here are quarter-end prices implied by the 13F filings. Today’s price on Yahoo Finance

Managers holding it, by quarter

0Q4 ’23
0Q1 ’24
0Q2 ’24
0Q3 ’24
0Q4 ’24
0Q1 ’25
0Q2 ’25
0Q3 ’25
0Q4 ’25
0Q1 ’26
1Q2 ’26
0Q3 ’26
Q4 ’23: 0; Q1 ’24: 0; Q2 ’24: 0; Q3 ’24: 0; Q4 ’24: 0; Q1 ’25: 0; Q2 ’25: 0; Q3 ’25: 0; Q4 ’25: 0; Q1 ’26: 0; Q2 ’26: 1; Q3 ’26: 0

Counts the managers on this site whose 13F for that quarter includes Ptc Therapeutics.

Who holds it

Each manager’s latest 13F, sorted by how much of their portfolio it is. Changes are against their previous quarter.

Managers holding Ptc Therapeutics
Polen Capital Management0.0%$2.0m$2.0mNew1 qtr

Download the holders: CSV · JSON · Markdown

Directors buying and selling

Open-market trades by directors, officers and 10% holders over the last 12 months. How this works
From their Form 4 filings with the SEC. Grants, option exercises and shares sold to pay tax are left out.
Insider purchases and sales of Ptc Therapeutics
Bought or soldFiling
14 Oct 2026Schmertzler MichaelDirector▼ Sold2,118$59.52$126kForm 4
14 Oct 2026Schmertzler MichaelDirector▼ Sold382$60.14$23kForm 4
9 Oct 2026Boulding Mark ElliottEXEC. VP AND CLO▼ Sold192$64.26$12kForm 4
7 Oct 2026Schmertzler MichaelDirector▼ Sold2,447$63.38$155kForm 4
7 Oct 2026Schmertzler MichaelDirector▼ Sold53$63.95$3kForm 4
6 Oct 2026Boulding Mark ElliottEXEC. VP AND CLO▼ Sold435$64.16$28kForm 4
5 Oct 2026Boulding Mark ElliottEXEC. VP AND CLO▼ Sold1,638$64.03$105kForm 4
30 Sep 2026Steele Glenn Jr Md PhdDirector▼ Sold12,000$65.16$782kForm 4
17 Sep 2026Schmertzler MichaelDirector▼ Sold9,624$67.83$653kForm 4
17 Sep 2026Schmertzler MichaelDirector▼ Sold376$68.45$26kForm 4
16 Sep 2026Schmertzler MichaelDirector▼ Sold7,006$67.35$472kForm 4
16 Sep 2026Schmertzler MichaelDirector▼ Sold2,994$66.58$199kForm 4
10 Sep 2026Schmertzler MichaelDirector▼ Sold10,000$67.34$673kForm 4
9 Sep 2026Schmertzler MichaelDirector▼ Sold9,428$67.79$639kForm 4
9 Sep 2026Schmertzler MichaelDirector▼ Sold572$68.67$39kForm 4
27 Aug 2026Schmertzler MichaelDirector▼ Sold11,890$71.55$851kForm 4
27 Aug 2026Schmertzler MichaelDirector▼ Sold610$72.22$44kForm 4
26 Aug 2026Schmertzler MichaelDirector▼ Sold6,874$72.74$500kForm 4
26 Aug 2026Schmertzler MichaelDirector▼ Sold5,626$73.18$412kForm 4
20 Aug 2026Schmertzler MichaelDirector▼ Sold9,419$70.78$667kForm 4

About the company

Sector
Health care · Pharmaceutical Preparations
Incorporated in
Delaware
Financial year ends
31 December
Shares outstanding
83m at 29 Jul 2026
SEC filings
Annual reports and other filings on EDGAR

Revenue and profit

$34.7m2013
$36.8m2015
$194m2017
$307m2019
$539m2021
$938m2023
$1.7bn2025
2013: $34.7m; 2014: $25.2m; 2015: $36.8m; 2016: $82.7m; 2017: $194m; 2018: $265m; 2019: $307m; 2020: $381m; 2021: $539m; 2022: $699m; 2023: $938m; 2024: $807m; 2025: $1.7bn
Ptc Therapeutics revenue and net income by year
YearRevenueNet income
2025$1.7bn$683m
2024$807m−$363m
2023$938m−$627m
2022$699m−$559m
2021$539m−$524m
2020$381m−$438m
2019$307m−$252m
2018$265m−$128m
2017$194m−$79.0m
2016$82.7m−$142m
2015$36.8m−$170m
2014$25.2m−$93.8m
2013$34.7m−$51.6m

From the company’s XBRL financial statements filed with the SEC, for each financial year. Gaps mean the company didn’t report that figure in a standard form.